Researchers and medical experts expressed concerns about the safety of Pfizer's Celebrex and Bextra, linking them to potential heart problems similar to those seen with Vioxx.
The FDA faced criticism for not acting sooner on Vioxx warnings, leading to questions about drug safety monitoring.
Merck's decision to withdraw Vioxx highlighted flaws in the drug approval process.
Pfizer is investigating Bextra's heart attack risk, following Merck's Vioxx withdrawal.
Patients are advised to consider alternatives to Cox-2 drugs, like over-the-counter pain relievers.
Overall, the Vioxx incident underscores the need for stricter, ongoing drug safety evaluations.
